Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Gain Therapeutics (GANX) Shares Outstanding (2020 - 2025)

Gain Therapeutics has reported Shares Outstanding over the past 6 years, most recently at $36.0 million for Q3 2025.

  • Quarterly results put Shares Outstanding at $36.0 million for Q3 2025, up 38.57% from a year ago — trailing twelve months through Sep 2025 was $36.0 million (up 38.57% YoY), and the annual figure for FY2024 was $27.1 million, up 67.42%.
  • Shares Outstanding for Q3 2025 was $36.0 million at Gain Therapeutics, up from $30.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding for GANX hit a ceiling of $36.0 million in Q3 2025 and a floor of $11.9 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $12.6 million (2023), compared with a mean of $17.9 million.
  • Biggest five-year swings in Shares Outstanding: surged 901.77% in 2021 and later changed 0.0% in 2022.
  • Gain Therapeutics' Shares Outstanding stood at $11.9 million in 2021, then changed by 0.0% to $11.9 million in 2022, then skyrocketed by 36.38% to $16.2 million in 2023, then soared by 67.42% to $27.1 million in 2024, then soared by 32.59% to $36.0 million in 2025.
  • The last three reported values for Shares Outstanding were $36.0 million (Q3 2025), $30.8 million (Q2 2025), and $28.7 million (Q1 2025) per Business Quant data.